↑ 1,01,11,2Röhrig B et al. Studientypen in der medizinischen Forschung: Teil 3 der Serie zur Bewertung wissenschaftlicher Publikationen. Dtsch Arztebl Int 2009; 106(15): 262-8.
↑Moons K. Prognosis and prognostic research: what, why, and how? BMJ 2008; 338:b375.
↑ 4,04,1Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33(11):1444-52.
↑Richards RG et al. A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol Assess 2002; 6:1-73.
↑Cutter GR et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999; 122: 871-82.
↑Hoogervorst EL et al. One year changes in disability in multiple sclerosis: neurological examination compared with patient self report. J Neurol Neurosurg Psychiatry 2003; 74:439-42.
↑Ziegler A et al. Verständnis von Nebenwirkungsrisiken im Beipackzettel: Eine Umfrage unter Ärzten, Apothekern und Juristen. Dtsch Arztebl Int 2013; 110(40): 669-73.
↑ 9,09,1Sormani MP et al. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol 2009; 65(3):268-75.
↑ 10,010,1Daumer M et al. MRI as an outcome in multiple sclerosis clinical trials. Neurology 2009; 72(8):705-11.
↑Brex PA et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002; 346:158-64.
↑Wiendl H et al. Aktuelle Übersicht zu fehlgeschlagenen und abgebrochenen Therapiestudien. Nervenarzt 2000; 71:597-610.
↑Jacobs LD et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39:285-94.
↑Rice GP et al. Interferon in relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 2001.